Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: A phase 2 extension study.

Competing Interests: Conflicts of interest Dr Querfeld received a research grant from Celgene; is a clinical investigator for Celgene, Trillium, miRagen, Bioniz, Kyowa Kirin; and is on Steering Committees/Boards for Helsinn, miRagen, Bioniz, Trillium, Kyowa Kirin, and Medivir. Dr Kim is on a Steering Committee for and has received research funding from Eisai; has received research funding from Forty Seven; is an Advisory Board member for Seattle Genetics; is a Steering Committee member and Advisory Board member for, and received research funding from, Kyowa Hakko Kirin; received research funding from Portola, Horizon; received research funding from Soligenix; is on a Steering Committee and Advisory Board for, and received research funding from, Innate; received research funding from Elorac; is on an Advisory Board for, and received research funding from, Galderma; is on a Steering Committee for, and received research funding from, Corvus; and received research funding from Trillium. Dr Guitart received research support from Galderma and Soligenix and is on Scientific Advisory Boards for Helsinn, Kyowa Kirin, miRagen, and Leo Pharma. Dr Scarisbrick is a consultant for Takeda, Helsinn, Recordati, 4SC, Kyowa, Mallinckrodt, and miRagen and has received a research grant from Kyowa. Dr Quaglino is on Advisory Boards for 4SC, Takeda, Actelion, Innate Pharma, Recordati Rare Diseases, Kyowa, and Therakos.